CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering

Dow Jones

Jul 12

By Josh Beckerman

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.

The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.

The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.

Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.

The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner.

Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 11, 2025 14:01 ET (18:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550496379"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550496379\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550496379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 02:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550496379","market":"sh","top_or_hot":-1,"title":"CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-12 02:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVM","symbol_name":"CEL-SCI Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550496379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550496379","pubTimestamp":1752256860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.Later Friday, CEL-SCI said ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVM":"CEL-SCI Corp","BK4139":"生物科技"},"translate_title":"沙特阿拉伯药物申报更新和股票发行后CEL-SCI飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVM":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n\n\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n\n\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n\n\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n\n\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n\n\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n\n\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 14:01 ET (18:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}